Hetero Healthcare Ltd. launches Perzea – India’s most affordable Pertuzumab, in collaboration with EnzeneThe product, a targeted therapy for HER2-positive breast cancer, has been introduced through a semi-exclusive collaboration with Enzene Biosciences Ltd.By Telangana Today Updated On - 22 September 2025, 01:33 PMHyderabad: In a strategic step to democratise access to advanced cancer therapies, Hetero Healthcare Ltd., one of India’s leading pharmaceutical companies, has announced the launch of Perzea, its most affordable biosimilar of Pertuzumab. The product, a targeted therapy for HER2-positive breast cancer, has been introduced through a semi-exclusive collaboration with Enzene Biosciences Ltd. With the launch of Perzea, Hetero Healthcare seeks to reduce cost barriers, enabling thousands of patients in India to access advanced treatment options and improving overall outcomes. Leadership Commentary Mr. M. Srinivas Reddy, Managing Director, Hetero Healthcare Ltd., said:“At Hetero Healthcare, our focus has always been on innovation and affordability. With a strong presence in oncology, antiretrovirals, and critical care, Hetero Healthcare continues to expand its reach and innovate to improve patient outcomes across India.